Review
Pharmacology & Pharmacy
Yang Liu, Xianzhong Deng, Zhi Wen, Jing Huang, Chongjian Wang, Caixia Chen, Erhao Bao, Jiahao Wang, Xuesong Yang
Summary: This study aimed to comprehensively assess the efficacy of multiple treatment regimens for metastatic castration-resistant prostate cancer (mCRPC) through a network meta-analysis (NMA) of randomized controlled trials (RCTs). The results showed that chempretarget, PARP inhibitors, and chempre significantly improved survival outcomes for mCRPC patients. These findings have important implications for treatment decision-making in mCRPC and may guide the development of more effective therapeutic strategies.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Environmental Sciences
Fatai A. Adewuyi, Pablo Knobel, Priyanka Gogna, Payam Dadvand
Summary: This systematic review found that green prescriptions can have positive effects on psychological health and wellbeing, cardiometabolic health, physical activity, and inflammation. However, there is a lack of studies on the effects of green prescriptions on orthopedic conditions, pain, and recovery from exhaustion disorder. More research with larger sample sizes and objective measures is needed.
ENVIRONMENTAL RESEARCH
(2023)
Article
Dermatology
Kevin S. Kim, An-Wen Chan, Emilie P. Belley-Cote, Aaron M. Drucker
Summary: Noninferiority trials, which assess the comparability of a new treatment with the standard of care, have increased significantly in publication from 2005 to 2015. These trials differ from superiority trials in various aspects of trial design and have unique considerations.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Review
Endocrinology & Metabolism
Irfan Vardarli, Susanne Tan, Tim Brandenburg, Frank Weidemann, Rainer Goerges, Ken Herrmann, Dagmar Fuehrer
Summary: This study conducted a comprehensive meta-analysis to evaluate the risk and incidence of endocrine immune-related adverse effects (eirAEs) in solid tumors treated with immune checkpoint inhibitor (ICI) monotherapy or combination therapy. The results showed that ICI therapy significantly increased the risk and incidence of eirAEs, with combination therapy having a higher risk for hypophysitis/hypopituitarism.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Multidisciplinary Sciences
Christopher Jackson, Alexandra L. J. Freeman, Zsofia Szlamka, David J. Spiegelhalter
Summary: This meta-analysis identified and quantified a range of potential adverse effects associated with bisphosphonate drugs in breast cancer patients, most of which are clinically recognized. The study showed that bisphosphonate drugs may lead to various adverse effects, but there was little variation in side effects between patients of different ages, menopausal status, cancer types, and concurrent breast cancer therapies.
Review
Pharmacology & Pharmacy
Jose Diogo R. Souza, Julia Cozar Pacheco, Giordano Novak Rossi, Bruno. O. O. de-Paulo, Antonio. W. W. Zuardi, Francisco. S. S. Guimaraes, Jaime E. C. Hallak, Jose Alexandre Crippa, Rafael. G. G. Dos Santos
Summary: Recent RCTs involving oral CBD administration for at least a week suggest that CBD has a good safety and tolerability profile, confirming previous data. However, it can potentially interact with other drugs and its use should be monitored, especially at the beginning of treatment.
Review
Oncology
Bisheng Cheng, Shuchao Ye, Peiming Bai
Summary: Through meta-analysis, this study found that cytoreductive surgery was superior to endocrine therapy in terms of overall survival, cancer-specific survival, and progression-free survival in patients with oligometastatic prostate cancer. Therefore, compared with endocrine therapy, cytoreductive surgery may be a more suitable approach for treating oligometastatic prostate cancer.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Tung Hoang, Dae Kyung Sohn, Byung Chang Kim, Yongjun Cha, Jeongseon Kim
Summary: This study aimed to compare the efficacy and safety of systemic therapies for the treatment of advanced or metastatic colorectal cancer (CRC). The findings suggest that FOLFIRI/FOLFOX/FOLFOXIRI + bevacizumab had the best overall response rate (ORR) and disease control rate (DCR) compared to other treatments. However, treatments were comparable in terms of adverse events and serious adverse events. The study highlights the importance of considering different treatment options for CRC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Olivia Pagani, Barbara A. Walley, Gini F. Fleming, Marco Colleoni, Istvan Lang, Henry L. Gomez, Carlo Tondini, Harold J. Burstein, Matthew P. Goetz, Eva M. Ciruelos, Vered Stearns, Herve R. Bonnefoi, Silvana Martino, Charles E. Geyer, Claudio Chini, Fabio Puglisi, Simon Spazzapan, Thomas Ruhstaller, Eric P. Winer, Barbara Ruepp, Sherene Loi, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan, Prudence A. Francis
Summary: The combined analysis of SOFT-TEXT compared the outcomes of 4,690 premenopausal women with ER/PgR+ early breast cancer randomly assigned to exemestane + OFS or tamoxifen + OFS. Exemestane + OFS showed significant improvement in DFS and DRFI, but not overall survival, compared to tamoxifen + OFS. This study provides guidance for selecting patients who may benefit from exemestane over tamoxifen in the setting of OFS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Zhanpeng Liang, Sihong Lin, Huiqin Lai, Luzhen Li, Jiaming Wu, Huatang Zhang, Cantu Fang
Summary: This systematic review and meta-analysis found that adding endocrine therapy to salvage radiotherapy is more effective than salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Psychiatry
Guangli Lu, Ruiying Jia, Dandan Liang, Jingfen Yu, Zhen Wu, Chaoran Chen
Summary: The study demonstrated that music therapy can significantly reduce anxiety levels, particularly for participants of different ages, national development levels, and number of therapy sessions.
PSYCHIATRY RESEARCH
(2021)
Article
Oncology
Ming Xie, Yan Zhong, Yide Yang, Fang Shen, Yue Nie
Summary: The study revealed that extended adjuvant endocrine therapy can improve disease-free survival, overall survival, relapse-free survival, distant metastatic-free survival, reduce the incidence of new breast cancer, but also increase the risk of bone fracture and osteoporosis.
FRONTIERS IN ONCOLOGY
(2022)
Review
Nutrition & Dietetics
Ya-Feng Yang, Preety Babychen Mattamel, Tanya Joseph, Jian Huang, Qian Chen, Babatunde O. Akinwunmi, Casper J. P. Zhang, Wai-Kit Ming
Summary: This systematic review and meta-analysis investigated the efficacy of low-carbohydrate ketogenic diet (LCKD) as an adjuvant therapy in antitumor treatment compared to non-ketogenic diet. The results showed significant outcomes in terms of prostate-specific antigen (PSA), achievement of ketosis, and level of satisfaction in the LCKD group. However, overall there was insufficient evidence to support the beneficial effects of LCKDs on antitumor therapy, highlighting the need for more trials with larger sample sizes for a conclusive result.
Review
Surgery
Mei Liu, Shengqiang Qian, Jing Wu, Jing Xiao, Xiaohua Zeng
Summary: The meta-analysis suggests that the addition of Zoledronic acid (ZA) to neoadjuvant therapy does not improve the pathological complete response (pCR) rate in breast cancer patients. However, there might be a potential benefit in postmenopausal women and patients with triple-negative breast cancer. Furthermore, the use of ZA does not show benefits in objective response rate, breast-conserving surgery rate, or recurrence rate, and may increase the risk of mortality.
ASIAN JOURNAL OF SURGERY
(2023)
Review
Urology & Nephrology
Ting Martin Ma, Fang-I Chu, Howard Sandler, Felix Y. Feng, Jason A. Efstathiou, Christopher U. Jones, Mack Roach, Seth A. Rosenthal, Thomas Pisansky, Jeff M. Michalski, Michel Bolla, Theo M. de Reijke, Philippe Maingon, Anouk Neven, James Denham, Allison Steigler, David Joseph, Abdenour Nabid, Luis Souhami, Nathalie Carrier, Luca Incrocci, Wilma Heemsbergen, Floris J. Pos, Matthew R. Sydes, David P. Dearnaley, Alison C. Tree, Isabel Syndikus, Emma Hall, Clare Cruickshank, Shawn Malone, Soumyajit Roy, Yilun Sun, Nicholas G. Zaorsky, Nicholas G. Nickols, Robert E. Reiter, Matthew B. Rettig, Michael L. Steinberg, Vishruth K. Reddy, Michael Xiang, Tahmineh Romero, Daniel E. Spratt, Amar U. Kishan
Summary: The study aimed to evaluate the prognostic impact of local failure and the dynamics of distant metastasis following radiotherapy. The results showed that local failure was an independent prognosticator of overall survival, prostate cancer-specific survival, and distant metastasis-free survival in high-risk prostate cancer patients, and it was significantly associated with distant metastasis-free survival in intermediate-risk patients. Additionally, the study found that a "second wave" of distant metastases occurred subsequent to local failure events.
